Copy number variation of molecular targets, as assessed in both tumour and cfDNA, has been shown to impact on therapeutic targeting of ERBB2, FGFR, and EGFR, with high level amplifications being associated with more favourable responses [12,13,14]. The gene discussed is ERBB2; the disease is neoplasm.